How to Buy Beam Therapeutics Stock
Beam Therapeutics Inc
Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
Beam Therapeutics stock last closed at $26.29, down 0.38% from the previous day, and has increased 5.16% in one year. It has overperformed other stocks in the Biotechnology industry by 0.31 percentage points. Beam Therapeutics stock is currently +26.15% from its 52-week low of $20.84, and -46.89% from its 52-week high of $49.50.
At the moment, there are 82.81M shares of BEAM outstanding. The market cap of BEAM is $2.18B. In the past 24 hours, 1.27M BEAM shares were traded.
How to Buy Beam Therapeutics Stock
Not sure how to invest in Beam Therapeutics stock? Here's how.
- Figure out where to buy Beam Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Beam Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your method of payment and add your information.
- Evaluate Beam Therapeutics stock: The Beam Therapeutics ticker symbol is BEAM. Is Beam Therapeutics stock a good investment? Should you buy shares of BEAM? How do BEAM's underlying business fundamentals look? Do top analysts think Beam Therapeutics is a good buy? Why has BEAM's stock price moved recently? (Hint: Our stock market analysis website can help you understand if BEAM is a good stock to buy).
- Place your BEAM purchase: Decide if you will purchase BEAM shares at the current market price or use a limit order to buy BEAM stock at a particular price.
- Monitor your BEAM investment: Create a watchlist to monitor your position in Beam Therapeutics stock.
Step 1: Figure out where to buy Beam Therapeutics stock
You will need an online brokerage account in order to access the NASDAQ market and buy BEAM shares.
Our favorite brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world financial markets: From Technology to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen your brokerage, the next step is to fill out some personal details so you are able to buy BEAM stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open a new brokerage account.
- Submit your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've created your account on the highest rated app to buy and sell stocks, you can securely and quickly fund your account:
Watch the video below for more details depositing funds into your investment account.
Step 4: Evaluate Beam Therapeutics stock
After you have identified the best place to buy Beam Therapeutics stock, it's crucial to evaluate their stock prior to investing, so you truly wrap your head around the risk as well as the upside.
Beam Therapeutics shares quick numbers
BEAM Due Diligence Score
WallStreetZen was designed to help part-time investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on BEAM's stock page.
Is BEAM stock undervalued or overvalued?
You can use many financial metrics, analyses, models, and charts to gauge BEAM's true value.
Using relative valuations metrics:
- BEAM could be undervalued based on its P/B ratio of 2.75x, relative to Biotechnology industry P/B ratio of 4.95x
You can access more valuation research on BEAM's stock here.
BEAM Financial Health Summary
Positive Financial Indicators:
- There are more short-term assets than short-term liabilities on the BEAM balance sheet.
- BEAM has $932.31M in cash and short term investments. This is enough to cover its annual cash burn of $145.37M.
- BEAM has cash burn of 145373000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the BEAM balance sheet.
- Total BEAM debt is lower than 5 years ago, relative to shareholder equity.
Negative Financial Indicators:
- BEAM has a relatively high debt to equity ratio of 0.48.
- BEAM profit margin has gone up by 3.44 percentage points in the past year, but the company is still unprofitable.
Do Wall Street analysts think it's a good time to buy BEAM stock
Out of 7 Equities analysts who monitor BEAM, the consensus analyst rating on Beam Therapeutics is a Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest BEAM Analyst Forecasts
Eric Joseph, a bottom 4% analyst from JP Morgan maintains BEAM with a strong buy rating and raises their BEAM price target from $45.00 to $48.00, on Aug 7, 2024.
Gena Wang, a bottom 4% analyst from Barclays maintains BEAM with a hold rating and lowers their BEAM price target from $33.00 to $31.00, on Aug 7, 2024.
You can dive deeper into what analysts are saying on the Beam Therapeutics stock forecast page.
BEAM Technical Indicators
Is BEAM Growing Revenue?
Last year, BEAM revenue was $349.64M. During the last 5 year, BEAM's revenue has gone up by 681.43% per year. This was faster than the Biotechnology industry average of 61.2%.
Dive into BEAM's earnings and revenue performance here.
What are BEAM insiders up to?
Over the past year, executives and large shareholders at BEAM have sold more shares than they have bought.
Christine Bellon, Chief Legal Officer of BEAM, was the latest BEAM insider to sell. They sold $30,627.88 worth of BEAM stock on Jan 2, 2025.
Learn more about who owns BEAM stock here.
Does BEAM stock generate passive income?
No, Beam Therapeutics doesn't provide an income stream by paying out dividends.
BEAM Social Trading Data
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Place your BEAM purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount, place a limit order.
Press the Open button and eToro will place the order.
If you require more help with buying stocks on eToro, watch the how to video below:
Step 6: Monitor your BEAM investment
Now that you own some BEAM stock, you'll want to stay up-to-date on your investment.
Put BEAM on a watchlist to get the latest updates about your BEAM stock.
BEAM Feed
How to Buy Stock in Beam Therapeutics
To reiterate, here are the 6 steps for buying Beam Therapeutics stock:
- Figure out where to buy Beam Therapeutics stock
- Open your brokerage account
- Deposit funds into your investment account
- Evaluate Beam Therapeutics stock
- Place your BEAM purchase
- Monitor your BEAM investment
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get updates on your investment in Beam Therapeutics, click below.
More "How To" Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.